Peter McCormack1, Francisco Sapunar. 1. AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, UK. peter.mccormack@astrazeneca.com
Abstract
PURPOSE:Fulvestrant is at least as effective as anastrozole in the treatment of postmenopausal women with advanced breast cancer whose disease has previously progressed or recurred on antiestrogen therapy. Pharmacokinetic data have shown that, at the approved dose (250 mg/month), it takes approximately 3-6 months for fulvestrant to reach steady-state levels. Theoretically, a more rapid attainment of steady state might reduce the number of early progressions. A pharmacokinetic model simulating plasma concentrations expected to be achieved with a fulvestrant loading dose (LD) regimen suggested that steady state might be achieved earlier with the LD. The aim of this study was to characterize the pharmacokinetics of the fulvestrant LD regimen. This pharmacokinetic substudy was conducted within a phase III trial, EFECT (Evaluation of Fulvestrant versus Exemestane Clinical Trial), comparing fulvestrant with exemestane in postmenopausal women with hormone-sensitive advanced breast cancer whose disease had progressed or recurred following nonsteroidal aromatase inhibitor treatment. PATIENTS AND METHODS: Patients received fulvestrant intramuscularly using a LD regimen of 500 mg on day 0, 250 mg on days 14 and 28, and then 250 mg each month thereafter. Blood samples were collected throughout the first month and on day 28 of each subsequent month. Plasma fulvestrant concentrations were determined by highperformance liquid chromatography-mass spectrometry, and pharmacokinetic parameters were estimated with nonlinear mixed-effects modeling. RESULTS:Thirty-seven patients receiving fulvestrant were enrolled into the pharmacokinetic substudy, and 269 fulvestrant plasma concentrations were recorded. Maximum fulvestrant concentration (19.7 ng/mL) was observed at an average of 12 days within the first month and maintained at 12-15 ng/mL throughout the remainder of the dosing period. CONCLUSION:Steady-state plasma levels were attained within the first month of treatment with fulvestrant LD, in line with the predictions of the pharmacokinetic model.
RCT Entities:
PURPOSE:Fulvestrant is at least as effective as anastrozole in the treatment of postmenopausal women with advanced breast cancer whose disease has previously progressed or recurred on antiestrogen therapy. Pharmacokinetic data have shown that, at the approved dose (250 mg/month), it takes approximately 3-6 months for fulvestrant to reach steady-state levels. Theoretically, a more rapid attainment of steady state might reduce the number of early progressions. A pharmacokinetic model simulating plasma concentrations expected to be achieved with a fulvestrant loading dose (LD) regimen suggested that steady state might be achieved earlier with the LD. The aim of this study was to characterize the pharmacokinetics of the fulvestrant LD regimen. This pharmacokinetic substudy was conducted within a phase III trial, EFECT (Evaluation of Fulvestrant versus Exemestane Clinical Trial), comparing fulvestrant with exemestane in postmenopausal women with hormone-sensitive advanced breast cancer whose disease had progressed or recurred following nonsteroidal aromatase inhibitor treatment. PATIENTS AND METHODS: Patients received fulvestrant intramuscularly using a LD regimen of 500 mg on day 0, 250 mg on days 14 and 28, and then 250 mg each month thereafter. Blood samples were collected throughout the first month and on day 28 of each subsequent month. Plasma fulvestrant concentrations were determined by highperformance liquid chromatography-mass spectrometry, and pharmacokinetic parameters were estimated with nonlinear mixed-effects modeling. RESULTS: Thirty-seven patients receiving fulvestrant were enrolled into the pharmacokinetic substudy, and 269 fulvestrant plasma concentrations were recorded. Maximum fulvestrant concentration (19.7 ng/mL) was observed at an average of 12 days within the first month and maintained at 12-15 ng/mL throughout the remainder of the dosing period. CONCLUSION: Steady-state plasma levels were attained within the first month of treatment with fulvestrant LD, in line with the predictions of the pharmacokinetic model.
Authors: Harold J Burstein; Constance T Cirrincione; William T Barry; Helen K Chew; Sara M Tolaney; Diana E Lake; Cynthia Ma; Kimberly L Blackwell; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Deepti Mathur; Bradford P Taylor; Walid K Chatila; Howard I Scher; Nikolaus Schultz; Pedram Razavi; Joao B Xavier Journal: Mol Cancer Ther Date: 2022-05-04 Impact factor: 6.009
Authors: Christophe Morisseau; Svitlana Pakhomova; Sung Hee Hwang; Marcia E Newcomer; Bruce D Hammock Journal: Bioorg Med Chem Lett Date: 2013-05-06 Impact factor: 2.823
Authors: A Harrod; J Fulton; V T M Nguyen; M Periyasamy; L Ramos-Garcia; C-F Lai; G Metodieva; A de Giorgio; R L Williams; D B Santos; P J Gomez; M-L Lin; M V Metodiev; J Stebbing; L Castellano; L Magnani; R C Coombes; L Buluwela; S Ali Journal: Oncogene Date: 2016-10-17 Impact factor: 9.867